PV Bulletin
Health Sciences Authority (HSA) SingaporeSingapore

Extension of e-labelling to P and GSL medicines

The Health Sciences Authority's Therapeutic Products Branch announced an extension of electronic labelling to Pharmacy-only (P) and General Sale List (GSL) medicines, effective 30 June 2026.

PV Impact Brief

Urgency: HighConfidence: high
Relevant for
Regulatory Intelligence LeadLabeling LeadQPPV
Processes impacted
Labeling
Action needed

Manufacturers must adjust labeling workflows to incorporate e-labelling mechanisms, such as QR codes, for P and GSL medicines by the stipulated date.

Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Regulatory Update / Notice
Policy status
new
Publication date
2026-06-30
Policy change
The Health Sciences Authority's Therapeutic Products Branch (TPB) announced an extension of electronic labelling (e-labelling) to Pharmacy-only (P) and General Sale List (GSL) medicines, effective 30 June 2026. This initiative follows the previous implementation for Prescription-only Medicines (POM) and aims to enhance digital access to product information.

Key changes

Extension of the e-labelling scheme to include P and GSL categories of therapeutic products. Manufacturers and registration holders can now provide product information through digital means (e.g., QR codes) instead of or in addition to physical leaflets for these categories.

Affected workflows

Labeling

Responsible groups

Regulatory AffairsLabeling OperationsPharmacovigilance

PV impact

Improved accessibility to the latest product information and safety updates for healthcare professionals and consumers. This affects labeling workflows and requires updates to registration and packaging processes for MAHs.

View regulator source

Source document details

Extracted documents

Unable to extract linked source document: https://www.googletagmanager.com/ns.html

Evidence and confidence

Confidence: highSource updated: Jun 30, 2026

Full briefing

What changed

The extension of the e-labelling scheme to include Pharmacy-only (P) and General Sale List (GSL) medicines effective from 30 June 2026.

Why it matters

This initiative enhances digital access to product information and safety updates, thus improving the labeling workflows and requiring updates to registration and packaging processes for Marketing Authorization Holders (MAHs).

Practical implication

Manufacturers must adjust labeling workflows to incorporate e-labelling mechanisms, such as QR codes, for P and GSL medicines by the stipulated date.

#labeling#Safety Signals#new#policy-change#firecrawl-policy-agent#Regulatory Update / Notice#Health Sciences Authority (HSA) Singapore

Related updates for your role

publicSaudi Food and Drug Authority (SFDA) · Saudi Arabia · Updated Jun 28, 2026

Regulations and Requirements for Conducting Clinical Trials on Drugs (Version 4.0)

Urgency: High

Ensure compliance with updated SUSAR reporting timelines (15 days), notify SFDA of Phase IV trials within 20 working days post-IRB approval, and prepare for the financial fee of 15,000 Saudi Riyals for clinical trial evaluations.

Country ComplianceICSRRegulatory Intelligence Lead
SOP Impact3 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead, QPPV
verifiedRegulatory action: Regulation
Read impact briefarrow_forward
publicDanish Medicines Agency · Denmark · Updated Jun 29, 2026

Clinical Trials E-mail Notifications Activation in CTIS

Urgency: High

CTIS users are now required to actively monitor notifications daily to ensure timely awareness of safety-related tasks.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Regulatory Update
Read impact briefarrow_forward
publicFrench National Agency for the Safety of Medicines and Health Products (ANSM) · France · Updated Jun 29, 2026

ANSM Training on Pharmacovigilance Signal Detection Methodologies

Urgency: High

Pharmacovigilance teams must adopt a structured classification approach to risk analysis, impacting how cases are assessed and notified.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Notice / Meeting
Read impact briefarrow_forward
publicTherapeutic Goods Administration (TGA) · Australia · Updated Jun 29, 2026

Summary of fees and charges to applications submitted to the TGA

Monitoring

Sponsors must prepare for increased costs tied to the submission and maintenance of products on the ARTG which will impact their regulatory budget planning and compliance processes.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Policy Update
Read impact briefarrow_forward